Exhibit 99.1
FOR IMMEDIATE RELEASE
| Contact: | Adam C. Derbyshire | Mike Freeman | ||||||
| Senior Vice President and | Executive Director, Investor Relations and | |||||||
| Chief Financial Officer | Corporate Communications | |||||||
| 919-862-1000 | 919-862-1000 | |||||||
SALIX PHARMACEUTICALS TO PRESENT AT
THOMAS WEISEL PARTNERS CONFERENCE
RALEIGH, NC, June 7, 2005 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Company will present at the 7th Annual Thomas Weisel Partners Growth Forum in San Francisco, CA on Tuesday, June 14 at 5:05 p.m. ET.
Interested parties can access a live audio web cast of the presentation athttp://www.salix.com. A replay of the presentation will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s 100-member gastroenterology specialty sales and marketing team. Salix markets COLAZAL®, XIFAXAN™, AZASAN®, ANUSOL-HC® and PROCTOCORT®. A granulated mesalamine product also is under development. Salix trades on the Nasdaq National Market under the ticker symbol “SLXP”.
For more information please contact the Company at 919-862-1000 or visit our web site atwww.salix.com. Information on our web site is not incorporated in our SEC filings.
